Eutilex.Co.,Ltd (KOSDAQ:263050)
1,496.00
+23.00 (1.56%)
At close: Apr 1, 2025, 3:30 PM KST
Eutilex.Co.,Ltd Company Description
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases.
It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies.
The company was founded in 2008 and is headquartered in Seoul, South Korea.
Eutilex.Co.,Ltd
Country | South Korea |
Founded | 2008 |
Industry | Biological Products, Except Diagnostic Substances |
Contact Details
Address: Suite 408, 4th Floor Seoul, 08591 South Korea | |
Phone | 82 2 2071 3310 |
Website | eutilex.com |
Stock Details
Ticker Symbol | 263050 |
Exchange | KOSDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | KRW |
SIC Code | 2836 |